Kuo‐Chen Chan

2.2k total citations · 1 hit paper
17 papers, 779 citations indexed

About

Kuo‐Chen Chan is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Cancer Research. According to data from OpenAlex, Kuo‐Chen Chan has authored 17 papers receiving a total of 779 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Surgery, 11 papers in Cardiology and Cardiovascular Medicine and 9 papers in Cancer Research. Recurrent topics in Kuo‐Chen Chan's work include Lipoproteins and Cardiovascular Health (13 papers), Lipid metabolism and disorders (11 papers) and Cancer, Lipids, and Metabolism (9 papers). Kuo‐Chen Chan is often cited by papers focused on Lipoproteins and Cardiovascular Health (13 papers), Lipid metabolism and disorders (11 papers) and Cancer, Lipids, and Metabolism (9 papers). Kuo‐Chen Chan collaborates with scholars based in United States, Canada and Netherlands. Kuo‐Chen Chan's co-authors include Robert Pordy, Daniel A. Gipe, Poulabi Banerjee, Daniel Gaudet, George D. Yancopoulos, Paolo Rubba, Shazia Ali, John J.P. Kastelein, Laurens F. Reeskamp and Robert S. Rosenson and has published in prestigious journals such as New England Journal of Medicine, Circulation and European Heart Journal.

In The Last Decade

Kuo‐Chen Chan

16 papers receiving 756 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evinacumab for Homozygous Familial Hypercholesterolemia

2020 470 citations Frederick J. Raal, Robert S. Rosenson et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kuo‐Chen Chan United States	7	504	480	341	219	91	17	779
Nagwa Khilla United States	5	610 1.2×	474 1.0×	314 0.9×	248 1.1×	65 0.7×	11	849
Shazia Ali United States	9	696 1.4×	548 1.1×	353 1.0×	283 1.3×	75 0.8×	37	1.0k
Hendrik du Toit Theron United States	5	517 1.0×	229 0.5×	222 0.7×	171 0.8×	53 0.6×	6	597
Konrad Schmidt Austria	6	383 0.8×	151 0.3×	135 0.4×	140 0.6×	65 0.7×	9	492
Stephan P. Babirak United States	7	348 0.7×	347 0.7×	328 1.0×	91 0.4×	99 1.1×	9	630
Robert A. Hegele Canada	5	509 1.0×	158 0.3×	241 0.7×	199 0.9×	83 0.9×	5	641
Ana Catarina Alves Portugal	19	662 1.3×	189 0.4×	235 0.7×	206 0.9×	124 1.4×	56	946
KaWah Li United Kingdom	8	490 1.0×	152 0.3×	168 0.5×	173 0.8×	60 0.7×	9	630
Raffaele Fresa Italy	10	390 0.8×	142 0.3×	172 0.5×	144 0.7×	91 1.0×	14	529
Alessia Di Costanzo Italy	18	247 0.5×	310 0.6×	374 1.1×	120 0.5×	92 1.0×	45	751

Countries citing papers authored by Kuo‐Chen Chan

Since Specialization

Citations

This map shows the geographic impact of Kuo‐Chen Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kuo‐Chen Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kuo‐Chen Chan more than expected).

Fields of papers citing papers by Kuo‐Chen Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kuo‐Chen Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kuo‐Chen Chan. The network helps show where Kuo‐Chen Chan may publish in the future.

Co-authorship network of co-authors of Kuo‐Chen Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Kuo‐Chen Chan. A scholar is included among the top collaborators of Kuo‐Chen Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kuo‐Chen Chan. Kuo‐Chen Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2023). The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. JACC Advances. 2(9). 100648–100648. 15 indexed citations

O’Brien, Meagan P., Andrea T. Hooper, Eduardo Forleo‐Neto, et al.. (2023). Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection. Open Forum Infectious Diseases. 10(12). ofad598–ofad598. 1 indexed citations

Brown, Elizabeth R., Meagan P. O’Brien, Flonza Isa, et al.. (2023). A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases. 10(7). ofad271–ofad271.

Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2021). The effect of evinacumab on LDL-C goal attainment in patients with homozygous familial hypercholesterolemia. Journal of clinical lipidology. 15(5). e7–e8. 1 indexed citations

Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2021). Abstract 12066: The Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. Circulation. 144(Suppl_1). 2 indexed citations

Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2020). Evinacumab for Homozygous Familial Hypercholesterolemia. New England Journal of Medicine. 383(8). 711–720. 470 indexed citations breakdown →

Rosenson, Robert S., Frederick J. Raal, Laurens F. Reeskamp, et al.. (2020). The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolemia Patients with Little to No Low-Density Lipoprotein Receptor Activity. Journal of clinical lipidology. 14(4). 552–552. 1 indexed citations

Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2020). Abstract 14267: Evinacumab Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia Irrespective of Background Lipid-lowering Medication. Circulation. 142(Suppl_3). 2 indexed citations

Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2020). Abstract 14407: The Longer-term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. Circulation. 142(Suppl_3). 2 indexed citations

10.

Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2020). The efficacy and safety of evinacumab in homozygous familial hypercholesterolaemia (HoFH) patients with little to no low-density lipoprotein receptor (LDLR) activity. Atherosclerosis. 315. e8–e8. 1 indexed citations

11.

Banerjee, Poulabi, Kuo‐Chen Chan, Asier Benito‐Vicente, et al.. (2019). Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis Thrombosis and Vascular Biology. 39(11). 2248–2260. 64 indexed citations

12.

Ahmad, Zahid, Poulabi Banerjee, Sara Hamon, et al.. (2019). Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation. 140(6). 470–486. 178 indexed citations

13.

Kostić, Ana, et al.. (2017). A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obesity and Metabolism. 20(2). 283–291. 24 indexed citations

14.

Gaudet, Daniel, Daniel A. Gipe, Kees Hovingh, et al.. (2017). Safety and Efficacy of Evinacumab, A Monoclonal Antibody to ANGPTL3, In Homozygous Familial Hypercholesterolemia. Journal of clinical lipidology. 11(3). 837–838. 3 indexed citations

15.

Hovingh, G. Kees, Daniel A. Gipe, Zahid Ahmad, et al.. (2017). 5938Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies. European Heart Journal. 38(suppl_1). 2 indexed citations

16.

Gaudet, Daniel, Daniel A. Gipe, Robert Pordy, et al.. (2016). Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies. Journal of clinical lipidology. 10(3). 715–715. 6 indexed citations

17.

Gaudet, Daniel, Daniel A. Gipe, Étienne Khoury, et al.. (2016). Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: A single-arm, open-label, proof-of-concept study. Atherosclerosis. 252. e254–e255. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact